MARKET

RARE

RARE

Ultragenyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

114.53
-1.18
-1.02%
After Hours: 114.53 0 0.00% 16:43 05/07 EDT
OPEN
113.67
PREV CLOSE
115.71
HIGH
117.50
LOW
112.05
VOLUME
664.27K
TURNOVER
--
52 WEEK HIGH
179.65
52 WEEK LOW
61.96
MARKET CAP
7.73B
P/E (TTM)
-36.7036
1D
5D
1M
3M
1Y
5Y
BRIEF-Ultragenyx - Entered Into Open Market Sale Agreementsm With Jefferies Relating To Shares Of Common Stock Offered By Prospectus Supplement
reuters.com · 1d ago
Global Phenylketonuria Drugs Market to Grow with a Significant CAGR Throughout 2021-2029; Rising Prevalence of Phenylketonuria Disorder Globally to Drive Market Growth
May 07, 2021 (AmericaNewsHour) -- Research Nester published a report titled "Phenylketonuria Drugs market- Global Demand Analysis and Opportunity Outlook...
AmericaNewsHour · 1d ago
Insider Selling at Ultragenyx Pharmaceutical (RARE) Continues with Significant Sale
MT Newswires · 2d ago
Allstate, Booking, CyberArk, Hilton and More Thursday Afternoon Analyst Calls
247WallSt.com · 2d ago
Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2021
 
Benzinga · 2d ago
Weighing in on vaccine patent waivers, Alcon and Ultragenyx upgraded at Citi and more in analyst action
Analysts weigh in on potential of COVID-19 patent waiversYesterday's announcement that the U.S. would support a waiver of IP protections for COVID-19 vaccines led to a slide in vaccine makers.However,
Seekingalpha · 2d ago
Evercore ISI Group Upgrades Ultragenyx Pharmaceutical to Outperform, Announces $144 Price Target
Evercore ISI Group analyst Liisa Bayko upgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from In-Line to Outperform and announces $144 price target.
Benzinga · 3d ago
--Evercore ISI Group Upgrades Ultragenyx Pharmaceutical to Outperform Rating From In-Line, Price Target is $144
MT Newswires · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RARE. Analyze the recent business situations of Ultragenyx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RARE stock price target is 152.63 with a high estimate of 195.00 and a low estimate of 80.00.
EPS
Institutional Holdings
Institutions: 334
Institutional Holdings: 73.60M
% Owned: 109.10%
Shares Outstanding: 67.46M
TypeInstitutionsShares
Increased
97
5.03M
New
62
1.82M
Decreased
70
2.27M
Sold Out
16
167.08K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Independent Director
Daniel Welch
President/Chief Executive Officer/Director
Emil Kakkis
Chief Financial Officer/Executive Vice President
Mardi Dier
Chief Human Resource Officer/Executive Vice President
Ernie Meyer
Executive Vice President/General Counsel
Karah Parschauer
Executive Vice President
Erik Harris
Executive Vice President
Dennis Huang
Executive Vice President
Thomas Kassberg
Executive Vice President
John Pinion
Other
Camille Bedrosian
Independent Director
William Aliski
Independent Director
Deborah Dunsire
Independent Director
Lars Ekman
Independent Director
Matthew Fust
Independent Director
Michael Narachi
Independent Director
Clay Siegall
Independent Director
Shehnaaz Suliman
No Data
  • All
  • Financials
  • Insiders
More
About RARE
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

Webull offers kinds of Ultragenyx Pharmaceutical Inc stock information, including NASDAQ:RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.